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Background. We have previously shown that 75% of individuals on antiretroviral therapy (ART) in a resource-limited setting
who experienced virological breakthrough to >1000copies/mL were resuppressed after an intensive adherence intervention. This
study examines the long-term outcomes of this group in order to understand the impact of the adherence intervention over
time. Methods.A R T - n a ¨ ıve adults commencing ART between September 2002 and December 2009 were reviewed. Those who
achieved suppression(<50copies/mL)were categorised by subsequent viralload: any>1000copies/mL(virologicalbreakthrough)
or not. Those with breakthrough were sub-categorised by following viral load into failed (VL>1000copies/mL) or resuppressed
(VL<1000copies/mL). Their outcome (lost-to follow-up, death, in care on ﬁrst-line therapy or in care on second-line therapy)
was determined as of the 13th April 2010. Findings. 4047 ART-na¨ ıve adults commenced ART. 3086 had >2 viral loads and were
included in theanalysis.2959achieved virologicalsuppression (96%).Thereafter 2109(71%) remained suppressed and850(29%)
experienced breakthrough (n = 283 (33%) failed and n = 567 (67%) resuppressed). Individuals with breakthrough were younger
(P<. 001), had lower CD4 counts (P<. 001), and higher viral loads (P<. 001) than those who remained suppressed. By 7 years
the risk ofbreakthrough was 42% and of failure 15%. Fewer adults with breakthrough remainin care over time (P<. 001).Lossto
care is similarwhether the individuals failed or resuppressed. Interpretation. While 67% of those who experience initial virological
breakthroughresuppress afteranadherenceintervention,theseindividualsaresigniﬁcantlylesslikelyberetained incarethanthose
who remain virologically suppressed throughout.
1.Introduction
Adherence to antiretroviral therapy is the key to successful
treatment outcomes at both individual and programmatic
levels.Ithasbeenshown thatindividualstaking95%ormore
oftheirmedicationwillmaintain virologicalsuppressionand
that this is readily achieved in resource-limited settings [1–
3]. More recent data from larger nonnucleoside-based ART
regimens show that these regimens allow for lower levels
of adherence after initial viral suppression, perhaps >80%,
before virological breakthrough occurs [4, 5].
Poor ART adherence can be assessed by the use of a se-
lection of objective or subjective adherence measures. These
include 3-day recall, a visual analogue scale [6], and a count
of tablet returns or pharmacy reﬁlls [7]. Many ART pro-
grammes in resource-limited settings have had the oppor-
tunity to implement adherence-focused systems from the
outset and have shown exceptionally high proportions of
individuals with virological suppression at any visit [8–
10].
Ifpoor adherence is persistent oris not detected,virolog-
ical breakthrough may occur. At this point, intensive adher-
ence support is required to initiate a change in tablet-
taking behaviour which can result in resuppression of
the HIV before resistance develops. In 2007, this group
showed that 75% of individuals with virological break-
through to >1000copies/mL resuppressed to <50copies/mL
at the subsequent viral load after an intensive adherence2 AIDS Research and Treatment
intervention [10]. The impact of this increase in viral load
on the longer term course of ART is unknown. There is a
possibilitythattheperiodofpooradherencewithsubsequent
inadequate ART drug levels may have allowed the HIV
to generate resistance mutations resulting in earlier failure
than observed in those with no episodes of virological
breakthrough.
In the previously published study, numbers of naive
adults on treatment were limited (n = 929) and outcomes
could only be determined to 32 months.
The objective of this study was to examine the long term
programmatic outcomes of individuals who had previously
experienced virological breakthrough to >1000copies/mL
and then resuppressed. We aimed to determine whether the
impact of the intervention was longstanding or whether it
resulted in diﬀering outcomes including increased rates of
virological failure and loss to followup/retention in care,
compared to those with continued virological suppression.
2.Methods
2.1. Site Description. Antiretroviral delivery at the Hannan
Crusaid Treatment Centre (HCTC) has been described
previously [10] .T h eH C T Ci so n eo ft h eD e p a r t m e n to f
Health ART sites in the Nyanga district, a township near
Cape Town, South Africa. An estimated 300,000 people live
in this district, which had an antenatal HIV-1 seroprevalence
rate of 27.9% in 2008 [11]. The clinic opened in September
2002 and by December 2009 cared for 2991 adults and 270
children needing ART. Antiretroviral therapy and associated
monitoring costs are provided free of charge in South
Africa. HIV RNA load and CD4 cell count assessments were
completed pretreatment and every 16 weeks while taking
ART. Viral load assays were done using the branch DNA
hybridisationtechnique(BayerHIV-1RNA3.0assay(branch
DNA)). Additional safety tests were performed according to
the 2004 edition of the national ART protocol and varied
according to the treatment regimen [12].
2.2. Drug Regimens. Until the 2010 edition of the South
African National Antiretroviral guidelines, ﬁrst-line ART
included stavudine (d4T), lamivudine (3TC), and either
efavirenz or nevirapine. Zidovudine (AZT) or tenofovir
could be substituted for d4T-related toxicity. ART for
second-line therapy included AZT, Didanosine (ddI), and
lopinavir/ritonavir [12, 13].
2.3. Adherence Support. The HCTC employed HIV-positive
lay counselors to educate each individual prior to initiating
ART and to provide on-treatment adherence support. Treat-
ment preparedness included three small group education
sessions and a home visit by a counselor assigned to the
area where the individual lived. Furtherhome visits occurred
monthly after starting treatment and continued until viral
suppression was achieved. Thereafter, home visits were only
carried out if the individual was ﬂagged as nonadherent,
experienced virological breakthrough, or was identiﬁed as a
defaulter through missed clinic visits.
2.4. Adherence Interventions. Patients on ART with a viral
load >1000copies/mL (virological breakthrough) at any
followup visit received a targeted adherence intervention.
These individuals were required to attend extracounselling
sessions, which focussed on adherence issues, and weekly
home visits were recommenced. The individual was issued
withapillboxandadosingdiary. Theviralloadwasrepeated
six toeightweeksafterthisintervention.Based onthesecond
test, patients were either regarded as having resuppressed
or having failed treatment. Patients with a second viral
load >1000copies/mL were prepared for second-line therapy
while resuppression to a viral load <1000copies/mL allowed
for continuation on ﬁrst-line therapy, with high-frequency
home visits continuing. If the viral load had fallen to
<50copies/mL routine clinic care was recommenced.
2.5. Study Design and Analysis. Data were accessed from
clinical (age, gender, WHO stage) and laboratory records
(CD4 counts and viral load) that were maintained on all
patients included in the HCTC ART programme. These
records were transferred on a weekly basis to an oﬀ-site
database. Outcomes which included death, loss to followup,
or transfer out were noted in the database and the date of the
outcome was captured.
2.6. Deﬁnitions. “Virological breakthrough” refers to any
individual whose viral load reached >1000copies/mL after
previous suppression to <50copies/mL. “Resuppressed”
refers to those individuals whose viral load subsequent to
the one at virological breakthrough was <1000copies/mL.
“Virological failure” refers to individuals with two consec-
utive viral loads >1000copes/mL. “Retention in care” refers
to individuals still receiving care either on-site or at another
site (transfer out). “Losses to care” included deaths and
individuals lost to followup.
2.7. Treatment Cohort. Patients commencing ART at the
clinic between 2 September 2002 and 31 December 2009
were reviewed retrospectively. Those <15 years of age and
those who were nonna¨ ı v ea te n t r yt ot h ep r o g r a m m ew e r e
excluded. Also excluded were those patients who had 1 or
no viral load after commencement of treatment as well as
thosewhoneverachievedvirologicalsuppressiononART.All
individuals who achieved suppression after ART commence-
ment and later experienced virological breakthrough were
analysed and divided into those who went on to virological
failure and those who resuppressed and continued on ﬁrst
line. Long-term outcomes including death, transfer out to
care in another service, or loss to followup were determined
for all individuals in the cohort.
2.8. Statistical Analysis. Demographic and baseline data
were described using medians and proportions as appro-
priate. Baseline characteristics were compared using non-
parametric statistics for data not normally distributed.
Patients were right censored on 13 April 2010 if they
remained in care. Patients who were more than 12 weeks
late for a scheduled visit were considered lost to followup,AIDS Research and Treatment 3
and their last visit to the clinic was used as last date in care.
Patients who were transferred out were considered to still
be in care at the time of censoring. Kaplan-Meier survival
analysis was used to assess risks of failure and loss to care.
2.9. Ethical Review. T h eU n i v e r s i t yo fC a p eT o w nR e s e a r c h
Ethics Committee approved data capture from the ART
site at the HCTC. All individuals who enrolled onto the
programme provided written informed consent.
3.Results
As of the 31st December 2009, 4967 individuals had com-
menced ART at the HCTC. After excluding 375 children
underthe age of 15 years and 545 adult individuals who were
transferred in on ART from another site, 4047 ART-na¨ ıve
adults were available for review (Figure 1). A further 961
people were excluded from the analysis since they had had
fewer than two viral loads on treatment, either as they died
early into treatment (n = 256, 27%), were lost to followup
(n = 258, 27%), transferred to care elsewhere (n = 121,
13%), or were within the ﬁrst eight months of treatment
(n = 326, 33%). A small proportion of the cohort never
suppressed on treatment and experienced early failure (n =
127, 4.1%). These individuals were also excluded (Figure 1).
The demographics of the remaining 2959 individuals used
f o rt h i sa n a l y s i sa r en o t e di nTable 1.
The majority of individuals had at least one point
where they suppressed their viral load to <50copies/mL
(n = 2959, 96%). Of those that initially suppressed on
treatment, the majority did not have a subsequent viral load
>1000copies/mL (n = 2109, 71%). The remaining 850 indi-
viduals (29%) experienced virological breakthrough in that
they had at least one viral load >1000copies/mL while on
treatment (Figure 1). Those with virological breakthrough
were signiﬁcantly younger, had a lower baseline CD4 count
(P = .0003), and a higher viral load (P = .002) than those
who remained suppressed throughout (Table 1).
Of the 850 individuals who experienced virological
breakthrough, 567 resuppressed and 283 failed virologically
(Figure 1). There was no signiﬁcant diﬀerence in the age
or stage between the above groups at baseline; however,
individuals who failed ART had signiﬁcantly lower CD4
counts and higher viral loads at baseline than those who
resuppressed.
The median time to breakthrough was 1.39 years (IQR
0.75–2.46 years), and to failure, 1.51 years (IQR 0.99–2.64
years). Figure 2 is a Kaplan-Meier survival curve showing
the risk of virological breakthrough and subsequent failure
for the whole cohort (n = 2959). At seven years into
treatment, up to 42% of the population on ART have a risk
of experiencing at least one viral load >1000 copies after
prior suppression. Only 15% have a risk of going on to fail
suggesting that 67% of those who experienced breakthrough
might be expected to resuppress at the next viral load.
Table 2 describes the long-term outcome of those who
resuppressed. Of those who never experienced virological
breakthrough 77% remained in care at the time of this study.
4047 ART-na¨ ıve
adults commenced
A R Tf r o mS e p t e m b e r
2002 to December
2009
3086 had 2 or more
v i r a ll o a dr e s u l t s
available
961 with only
1 viral load
available
2959 (96%)
suppressed viral load
(<1000copies/mL) on
treatment
127 (4%)
never
suppressed
(early failure)
2109 (71%) remain
suppressed viral load
(<1000copies/mL) on
treatment
850 (29%) experience
virological
breakthrough (at least
1V L>1000copies/mL)
567 (67%)
resuppressed with
adherence intervention ART
283 (33%) failed ﬁrst-line
Figure 1: A ﬂow diagram describing the cohort with virological
breakthrough (>1000copies/mL) as a subset of ART-na¨ ıve adults
commencing treatment at the HCTC and subsequent outcomes.
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Figure 2: A Kaplan-Meier survival curve depicting risk of an initial
virological breakthrough (ﬁrst viral load >1000copies/mL after
initialsuppression—lowercurve) andsubsequent riskofvirological
failure (second consecutive viral load >1000copies/mL—upper
curve). Of those with virological breakthrough an expected 66%
will resuppress after an adherence intervention.
There was some loss due to transfer out to another clinical
setting (n = 186, 8.9%) and to death (n = 64, 3.1%). Eleven
percent (n = 235) were lost to followup. The outcomes for
those who had a single viral load >1000copies/mL and who
then resuppressed diﬀer signiﬁcantly, with fewer remaining
in care (n = 348, 61%; P = .0000), largely as a function
of increased loss to followup (n = 123, 23%; P = .0000).4 AIDS Research and Treatment
Table 1
All na¨ ıve adults with initial viral suppression: n = 2959 Na¨ ıve adults with initial virological breakthrough: n = 850
Remain suppressed Initial viral
breakthrough Resuppressed Failed
Total number 2109 850 — 567 (67%) 283 (33%) —
Female gender:
n (%) 1415 (67) 585 (68) P = .7733∗ 386 (68) 200 (71) P = .7419∗
Age at treatment start:
mean years (±SD) 35 (±8.7) 33 (±8.0) P = .0000∗∗ 34 (±8.3) 32 (±7.5) P = .7591∗∗
WHO stage 1 or 2:
n (%) 611 (29) 228 (27) P = .5099∗ 159 (28) 67 (24) P = .2981∗
WHO stage 3 or 4:
n (%) 1495 (71) 622 (73) P = .7068∗ 406 (72) 216 (76) P = .5663∗
WHO stage unknown 3 0 — 0 0 —
Baseline CD4: median
cells/mm3 (IQR) 117 (62−168) 110 (50−163) P = .0003# 110 (57−171) 83 (34−138) P = .0000#
Baseline viral load:
median copies/mL
(IQR)
4.82 (4.39−5.26) 4.94 (4.51−5.30) P = .0002# 4.86 (4.48−5.24) 5.07 (4.70−5.48) P = .0000#
∗Chi-squared.
∗∗T-test.
#Mann-Whitney U test.
Table 2: Programmatic outcome of those who resuppressed com-
pared to those who never experienced virological breakthrough.
Never had
breakthrough
(n = 2109)
Breakthrough
and
resuppressed
(n = 567)
P value
Lost to followup:
n (%) 235 (11) 132 (23) P = .0000∗
Died on treatment:
n (%) 64 (3.1) 25 (4.4) P = .1184∗
Transfer out: n (%) 186 (8.9) 62 (11) P = .1623∗
Continue in care:
n (%)
(i) On ﬁrst line 1624 (77) 302 (53) P = .0000∗
(ii) Failed ﬁrst line 0 (0) 46 (8) P = .0000∗
∗Chi-squared (df = 1).
There was no signiﬁcant diﬀerencein proportion transferred
to care elsewhere (n = 62, 11%; P = .1623) or in deaths
(n = 25, 4.4%; P = .1184).
While all individuals who never experienced virological
breakthrough remain on ﬁrst-line therapy, 46 individuals
(8%) of those who resuppressed after breakthrough went on
to fail at a time subsequent to their next consecutive viral
load and switched to second-line therapy.
Figure 3 is a Kaplan-Meier survival curve showing the
risk of loss to care described above overtime. At seven years
into care, it can be expected that 78% of those who remain
suppressed throughout their ART remain in care. Losses are
due to either death or loss to followup. The curves for those
who experienced virological breakthrough do not diﬀer as
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Figure 3: A Kaplan-Meier survival curve depicting risk of loss to
care overtime. Losses include deaths and those lost to followup.
Those who never experience virological breakthrough are more
likely to remain in care overtime. Losses to care are greater in those
whoexperience breakthroughanddonotdiﬀer by future virological
outcomes (failed or resuppressed).
a function of resuppression or failure, with only 55–58% of
these groups remaining in care by 7 years.
4.Discussion
The objective of this study was to determine whether those
individuals on ART who experienced a single episode ofAIDS Research and Treatment 5
virological breakthrough after prior successful suppression
had similar long-term virological outcomes to individuals
who remain suppressed on ART throughout.
Of note, the majority of this treatment cohort achieved
virological suppression (96%), a much higher proportion
than noted in a recent systematic review of sub-Saharan
AfricanARTprogrammeswhere only78%oftreatedpatients
achievedvirologicalsuppression atsix months[14].Seventy-
one percent of this group continued to be suppressed at
the censor date for this analysis. Of the 29% who expe-
rienced virological breakthrough, two-thirds resuppressed
after the intensive adherence intervention: a similar pro-
portion to that seen in 2005 [10]. However, the risk of
experiencing virological breakthrough continued to increase
overtime, so that by seven years in care there was a relatively
high risk (42%) that an individual would have experi-
enced breakthrough and a 15% risk of failure of ﬁrst-line
therapy.
Preliminary data from 2005 showed that the risk of fail-
ure remained relatively low in individuals who had virolog-
ical breakthrough [10]. This study, of an expanded cohort,
suggests that these individuals have diﬀerent outcomes from
those who remained successfully suppressed. While 77% of
those who remained suppressed throughout were retained in
care seven years into the programme, this only applied to
58% of patients who experienced virological breakthrough.
This is largely a function of increasing loss to followup
overtime. These individuals were younger and more ill with
lower CD4 counts and higher viral loads at the time of
starting ART. It is of note that the risk of loss to followup
for patients who have virological breakthrough and then
resuppress is the same as for patients who fail treatment.
A systematic review of patient retention in ART pro-
g r a m m e se s t i m a t e dr a t e sa c r o s s3 3c o h o r t st or a n g ef r o m2 4
to77%at onlytwo yearsinto theprogramme. Deathand loss
to followup accounted for the majority of these losses, as in
our programme [15].
Although the overall outcomes of our programme may
seem reasonable compared to those of other current pro-
grammes, as the expansion of antiretroviral services con-
tinue, so must the eﬀort to improve adherence to care. While
our adherence intervention appears successful in that two-
thirds of those who experience virological breakthrough did
resuppress it is important to note that this intervention does
not impact on loss to followup.
Previous studies have identiﬁed subgroups of patients
who are at risk of LTFU. These include pregnant women and
younger people on ART [16]. This study identiﬁed patients
with virological breakthrough as another ofthese subgroups.
Itseems thatthosewhostruggletoadheretotherapy,initially
noted by an increase in viral load, signaling less than ideal
adherence to taking ART tablets, may also not adhere to the
program. It should also be considered that the intensity of
the adherence intervention itself, while successful for some
individuals, may deter others from remaining in care. It
is a weakness of this study that this is left to speculation.
Qualitative information from individuals lost to followup
from this programme would be required to answer this in
detail.
Intensive adherence programmes may result in retained
ﬁrst-line therapy for those individuals who have an initial
viral breakthrough but they do not of themselves retain peo-
ple in care. Remaining on ﬁrst-line therapy is an important
goal not only in terms of cost saving but also in terms
of preserving treatment options in resource-constrained
settings. However, increasing attention is being drawn to
retention to care in these settings in order to secure public
health impact. Adherence interventions should be targeted
to those who have an increased risk of loss to followup and
need to be broadened to address issues related to loss to care
as well as tablet-taking behavior.
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